KRAS G12C-mutated non-small cell lung cancer
Mirati Therapeutics Inc. focuses heavily on advanced non-small cell lung cancer with KRAS G12C mutation, including both non-squamous and broader lung cancer populations. Its studies examine treatment settings across first-line and previously treated disease, reflecting a strong emphasis on targeted approaches for lung tumours driven by this molecular alteration.
- Adagrasib in lung cancer
- KRAS G12C-targeted therapy
- First-line treatment for advanced NSCLC
- Previously treated metastatic disease
The sponsor also explores combinations with pembrolizumab and other systemic therapies in non-small cell lung cancer, highlighting a sustained interest in molecularly defined thoracic oncology.
Advanced colorectal cancer with KRAS G12C mutation
Mirati Therapeutics Inc. also funds research in advanced colorectal cancer carrying the KRAS G12C alteration. This area includes treatment options for patients whose disease has progressed after standard first-line therapy, with attention to targeted regimens designed for mutation-specific tumour biology.
- Colorectal cancer with KRAS G12C mutation
- Second-line treatment
- Cetuximab combinations
- Post-standard therapy disease progression
The colorectal programme extends the sponsor’s interest in precision oncology beyond lung cancer, with a clear focus on targeted combination therapy in mutation-selected disease.
Combination immuno-oncology strategies
A substantial part of the sponsor’s portfolio involves pairing KRAS G12C inhibitors with immune checkpoint inhibitors and other anticancer agents. These studies include combinations with pembrolizumab, nivolumab, and chemotherapy in advanced NSCLC, aiming to address treatment needs in both newly diagnosed and previously treated patients.
- Pembrolizumab-based combinations
- Nivolumab combinations
- Chemotherapy combinations
- Immunotherapy in lung cancer
This area links targeted oncology with immuno-oncology, showing interest in multi-agent treatment approaches for molecularly selected solid tumours.
Metastatic and treatment-resistant solid tumours
Mirati Therapeutics Inc. conducts trials in metastatic and treatment-resistant disease settings, particularly where prior exposure to platinum-based chemotherapy or other standard therapies has occurred. The sponsor’s research addresses patients with ongoing disease progression in advanced solid tumours, especially within lung and colorectal cancer populations.
- Metastatic NSCLC
- Disease progression after prior therapy
- Platinum-pretreated disease
- Advanced solid tumour oncology
The clinical programme reflects a sustained therapeutic interest in cancers with limited options after standard treatment exposure, particularly in precision medicine settings defined by KRAS G12C.
